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MECL1Proteasomes represent the major non-lysosomal mechanism responsible for the degradation of proteins. Fol-
lowing interferon γ treatment 3 proteasome subunits are replaced producing immunoproteasomes. Adeno-
virus E1A interacts with components of the 20S and 26S proteasome and can affect presentation of
peptides. In light of these observations we investigated the relationship of AdE1A to the immunoproteasome.
AdE1A interacts with the immunoproteasome subunit, MECL1. In contrast, AdE1A binds poorly to the protea-
some β2 subunit which is replaced by MECL1 in the conversion of proteasomes to immunoproteasomes.
Binding sites on E1A for MECL1 correspond to the N-terminal region and conserved region 3. Furthermore,
AdE1A causes down-regulation of MECL1 expression, as well as LMP2 and LMP7, induced by interferon γ
treatment during Ad infections or following transient transfection. Consistent with previous reports AdE1A
reduced IFNγ-stimulated STAT1 phosphorylation which appeared to be responsible for its ability to reduce
expression of immunoproteasome subunits.d).
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Adenovirus early region 1A (AdE1A) is the ﬁrst protein to be
expressed during viral infection and is essential for Ad-mediated
transformation (Berk, 2005; Frisch and Mymryk, 2002; Gallimore
and Turnell, 2001). AdE1A functions primarily through a complex se-
ries of protein–protein interactions, binding to, for example, transcrip-
tional co-repressors such as the Rb family and CtBP, co-activators such
as p300 and CBP and other proteins involved in chromatin modiﬁca-
tion such as TRRAP and p400 (Pelka et al., 2008; Gallimore and Turnell,
2001; Frisch and Mymryk, 2002). Two major forms of AdE1A are
expressed, translated from 12S and 13S RNAs. These protein products
are identical except for the presence of a transcriptional activation do-
main located towards the C-terminus of the larger molecule. Interac-
tion of this domain with cellular transcription factors is required for
expression of viral early region genes during infection (Jones, 1995).
Comparison of the amino acid sequences of E1A from a number of ad-
enovirus species, has allowed the identiﬁcation of four highly con-
served regions (CR1–4) (Kimelman et al., 1985; Avvakumov et al.,
2002, 2004). These regions account for about half of the amino acids
of each AdE1A and encompass the binding sites for many of the part-
ner proteins. The remaining sites of interaction are in the N-terminal30 residues, which have a limited degree of homology between differ-
ent serotypes. For example, the Rb family of proteins interact with
CR1 and CR2 (Dyson et al., 1992; Whyte et al., 1988), CBP/p300 with
the N-terminal region and CR1 (Eckner et al., 1994; Wang et al.,
1993), Mediator complex and TBP with CR3 (Boyer et al., 1999;
Webster and Ricciardi, 1991) and CtBP with CR4 (Boyd et al.,
1993). These, and many more, interactions are required for the efﬁ-
cacious functioning of AdE1A during viral infection and some are
necessary for transformation of mammalian cells in culture by
AdE1A together with a co-operating oncogene, such as AdE1B or
ras (Endter and Dobner, 2004).
In previous studies we have characterized the interactions of AdE1A
with subunits of the 26S proteasome (Grand et al., 1999; Turnell et al.,
2000; Zhang et al., 2004; Rasti et al., 2005, 2006).We have shown bind-
ing to components of the 19S regulatory complex aswell as the 20S pro-
teolytic core. Thus S8 interacts with the N-terminal region and CR3
(Rasti et al., 2005, 2006; Turnell et al., 2000), whereas S2 appears to
bind to CR2 of AdE1A (Zhang et al., 2004). Binding of AdE1A to S2
and/or S8 inhibits the ability of the 26S proteasome to degrade p53, at
least in vitro. Signiﬁcantly it has also been shown that AdE1A and the
26S proteasome are recruited to the promoters of Ad early genes during
infection (Rasti et al., 2006).
The proteasome is the major non-lysosomal mechanism involved
in protein degradation (Coux et al., 1996; Glickman and Ciechanover,
2002). The 20S complex is composed of 28 subunits which are ar-
ranged in four heptameric rings. α subunits form the upper and
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1997). Three β subunits (β1, β2 and β5) determine the proteolytic ac-
tivity of the proteasome. The 26S proteasome comprises the 20S pro-
teasome together with one or two 19S regulatory complexes. As well
as being responsible for general protein degradation the proteasome
is involved in the production of peptides for MHCI presentation. The
MHCI system is a vital component of the immune system that allows
the continuous surveillance of cells for the expression of foreign anti-
gens. In response to interferon γ (IFNγ) three subunits speciﬁc to the
immunoproteasome are expressed. LMP2, LMP7 and MECL1 substi-
tute for the constitutive components β1, β5 and β2 respectively
(Hisamatsu et al., 1996). The immunoproteasome has an altered
cleavage pattern, producing a rather different set of peptides for pre-
sentation and this has been seen as a mechanism for “ﬁne tuning”
the immune response (Gaczynska et al., 1994; Groettrup et al.,
2001; Rivett and Hearn, 2004). LMP2 and LMP7 are encoded within
the MHC locus, close to the TAP-1 and TAP-2 genes (Glynne et al.,
1991; Martinez and Monaco, 1991; Ortiz-Navarrete et al., 1991).
MECL-1 is not encoded in the MHC locus. These three subunits are re-
sponsible for the altered proteolytic activity of the immunoprotea-
some (Rivett and Hearn, 2004). Signiﬁcantly, more recent evidence
suggests that the primary function of the immunoproteasome may
not be the production of MHCI antigens but more probably the main-
tenance of protein homeostasis and the preservation of cell viability
in response to oxidative stress (Seifert et al., 2010).
It is nowwell established that AdE1A plays an important role in the
evasion and/or disruption of the host's immune system (Strath and
Blair, 2006; Blair and Blair-Zajdel, 2004). The expression of AdE1A
from Ad12, but not Ad5, was originally shown to down-regulate
MHCI expression on the surface of Ad transformed rodent cells
(Schrier et al., 1983; Bernards et al., 1983). This has been considered
to be responsible for the oncogenicity of Ad12, but not Ad5, trans-
formed rat cells when introduced back into the synegeic host. The
down-regulation of MHCI enables Ad12 transformed cells to avoid de-
tection by CD8+ T-cells (Yewdell et al., 1988). As well as affecting
MHCI expression AdE1A is able to down-regulate LMP2 expression
after transfection into human tumour cells possibly by inhibiting the
interaction of STATI with IRF1 (Chatterjee-Kishore et al., 2000;
Rotem-Yehudar et al., 1996). In addition, it has been shown that
other immunoproteasome subunits LMP7 and MECL1 as well as the
peptide transporter Tap-2, tapasin, PA28α and PA28β are expressed
at much lower level in Ad12 transformed rat cells than in Ad5 trans-
formed cells (Rotem-Yehudar et al., 1994, 1996; Vertegaal et al.,
2003). Furthermore, it has been shown that in a small panel of estab-
lished Ad transformed human cells LFA-3 and Fas, like MHC class I,
were expressed at lower level in the Ad12 transformants, making
them more susceptible to lymphokine activated killer (LAK) cells
(Bottley et al., 2005).
The present study represents the ﬁrst detailed examination of the
relationship of AdE1A to MECL1. We have shown the substitution of
immunoproteasome subunits for those of the “standard” constitutive
proteasome is accompanied by a marked change in the subunit bind-
ing of AdE1A, most obviously seen as a direct interaction with MECL1.
In addition it is apparent that, as with LMP2 and LMP7, AdE1A inﬂu-
ences the level of MECL1 expression in human cells.
Results
Association of AdE1A with proteasome subunits is long estab-
lished. It binds speciﬁcally to the S2 and S8 regulatory subunits
(Grand et al., 1999; Turnell et al., 2000; Zhang et al., 2004) and to
components of the 20S proteolytic core (Rasti et al., 2006). These in-
teractions appear to inhibit the proteolytic activity in vitro and to af-
fect AdE1Amediated transcriptional regulation. In the ﬁrst part of this
present study the interaction of AdE1A with the immunoproteasome
subunits LMP2, LMP7 and MECL1 was examined.AdE1A binds the immunoproteasome and MECL1
To conﬁrm the interaction of Ad5E1A with the immunoprotea-
some, H1299 cells were treated with IFNγ, infected with Ad5 and
immunoprecipitated after 24 h with antibodies against 20S α sub-
units, LMP7 and S8 (Fig. 1A). It can be seen that AdE1A was associated
with immunoproteasomes precipitated with the LMP7 antibody and
with complexes precipitated with the proteasome core α subunits
and the regulatory subunit S8 as has been shown previously. Interest-
ingly, rather more 13S E1A than 12S E1A was immunoprecipitated
with S8, probably attributable to the observation that S8 binds to
two sites on 13S E1A (N-terminal and CR3 regions) but only one on
12S E1A. To examine whether there was a direct interaction with
the immunoproteasome subunits, LMP2, LMP7 and MECL1 were radi-
olabelled with [35S]-methionine in in vitro transcription/translation
reactions. Incubation of these proteins with GST-E1A conﬁrmed that
Ad1213SE1A, Ad512SE1A and Ad513SE1A all bound to MECL1 but
not to LMP2 or LMP7 (Fig. 1B). To examine how the substitution of
the immune subunits (LMP2, LMP7 and MECL1) for the “standard”
subunits (β1, β5 and β2 respectively) affects binding to AdE1A a sec-
ond GST pull down experiment was performed. β1, β5 and β2 were
translated in the presence of [35S]-methionine and incubated with
GST-E1As (Fig. 1C). All E1As examined interacted with β1 and β5
but to a signiﬁcantly lesser extent with β2 (Fig. 1C) indicating a mod-
iﬁed binding proﬁle of AdE1A after the replacement of proteasome by
immunoproteasome subunits. It can be seen from the densitometric
scans shown in Fig. 1D that there is approximately a 3 fold reduction
in binding of the Ad1213SE1A and 6 fold reduction of Ad513SE1A
with β2 compared to MECL1. The reduction for Ad512SE1A is very
marked, with approximately 8 fold more protein bound to MECL1
than to β2.
MECL1 binds to the N-terminal region and CR3 of Ad5E1A
To determine the binding site on Ad5E1A, [35S]-methionine labelled
MECL1 was incubated with GST fragments spanning the Ad5E1Amole-
cule (Bruton et al., 2007).MECL1 bound to the N-terminal region and to
CR3 (Fig. 2A) but not to exon 2 or amino acids 41–140, encompassing
CR1 and CR2 and CR4. To examine the sites of interaction in more
detail, [35S]-methionine-labelled MECL1 was incubated with various
Ad512SE1A-GST proteins carrying single (or a double) amino acid sub-
stitutions in the N-terminal 30 amino acids (Rasti et al., 2005). It can be
seen that loss of the large hydrophobic residues (leucines at residues 19,
20, 23 and 28) resulted in appreciably reduced interaction (Figs. 2B and
C). In particular the L→A double substitution at residues 19 and 20was
deleterious to the interaction as has been observed for many other
AdE1A partner proteins (Rasti et al., 2005). However, mutation of L23,
I24 and, to a slightly lesser extent, L28 also reduced binding very signif-
icantly. To analyse the interaction of MECL1with Ad5E1ACR3 a panel of
deletion mutants was examined (Fig. 2D). Most of the deletions
resulted in reduced binding of MECL1, compared with the intact region.
However, the most marked diminution of binding was associated with
loss of the C-terminal element of CR3 (aa 180–204) such that both mu-
tants with deletion of aa180-184 and 188–204 bound MECL1 very
weakly. In a further experiment GST-E1ACR3 regions from a number
of different serotypes were incubated with [35S]-methionine labelled
MECL1. Interaction was observed with all the CR3 peptides conﬁrming
the generality of the association (Fig. 2E), although the extent of binding
varied.
The effect of adenovirus E1A on the expression of MECLI
In most cells in culture the level of expression of immunoprotea-
some subunits is low. However, in response to IFNγ this is markedly
increased. It is nowwell established that AdE1A can affect the expres-
sion of LMP2 and LMP7. It was therefore of considerable interest to
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Fig. 1. Adenovirus E1A binds to the immunoproteasome subunit MECL1. A, Co-immunoprecipitation of Ad5E1A with the immunoproteasome. H1299 cells were treated with IFNγ
for 24 h and infected for 24 h with Ad5. Proteins were immunoprecipitated with the antibodies shown, fractionated on a “urea gel” in the absence of SDS. Co-precipitating Ad5E1A
was detected by western blotting. The negative control antibody was raised against β actin. B, MECL1 binds directly to AdE1A. LMP2, LMP7 and MECL1 were labelled with [35S]-
methionine by in vitro transcription and translation. The labelled proteins were incubated with GST-E1As. Bound protein was resolved by SDS-PAGE and radioactive species
detected by autoradiography. C, AdE1A binds weakly to the proteasomal subunit β2. β2, β5 and β7 were labelled with [S35]-methionine by in vitro transcription and translation
and incubated with GST-E1As as shown. Bound proteins were fractionated by SDS-PAGE and detected by autoradiography. Input represents 5% of the total input. D, Densitometric
scans of gels shown in 1B and 1C as well as repeats of the experiment (n=3).
151S. Berhane et al. / Virology 421 (2011) 149–158determine whether AdE1A could also inhibit the expression of MECL1.
The effect of E1A was examined against 3 human cell backgrounds: in
established adenovirus transformed human cell lines, in virally
infected cells and in human cells transiently transfected with AdE1A.
In an initial examination the relative levels of immunoproteasome
components were examined in a large panel of adenovirus transformed
human cell lines. In the absence of IFNγ, expression of MECL1, LMP2 or
LMP7 was not detected (data not shown). Addition of IFNγ for 48 h
caused up-regulation of LMP2 and LMP7 in cell lines expressing
Ad5E1A but not Ad12E1A (Figs. 3A and B). However, only a trace of
MECL1 was seen in any of the Ad5E1A transformed cells and none in
the Ad12 transformants (Fig. 3B). The complementary oncogene (E1B
or ras) to AdE1A seemed to have no effect on the expression—there
appeared to be a shut-off of immunoproteasome expression with
Ad12E1A irrespective of the expression of activated (mutant) H-ras,
N-ras or Ad12E1B proteins. In the Ad5 transformants induction oc-
curred, again, irrespective of the presence of mutant ras or Ad5E1B
(Fig. 3). It can be seen that there was some variation in the relative ex-
pression of LMP2 and LMP7 subunits (Fig. 3B).
In view of the results obtained with established Ad transformed
human cell lines which showed that Ad12E1A but not Ad5E1A wasprimarily responsible for reduced expression of immunoproteasome
components following IFNγ treatment, we examined the effect of
transient transfection of AdE1A into human cells. When H1299 cells
were treated with IFNγ appreciable induction of the immunoprotea-
some subunits was observed. However, transfection of either
Ad512SE1A or Ad513SE1A resulted in a marked reduction in the
level of expression of the immunoproteasome subunits after IFNγ
treatment (Fig. 4A). This was particularly marked in the case of
MECL1 where no subunit was visable after Ad5E1A transfection. Sim-
ilarly, Ad12E1A reduced the IFNγ inducible expression of LMP2, LMP7
andMECL1 (Fig. 4B) although not entirely as is the case with Ad5. (Ef-
ﬁciency of transfection was in excess of 80% in most cases and is
shown in Table 1). These observations may be contrasted with the sit-
uation in established Ad transformed human cell lines where
Ad12E1A had a much more marked effect than Ad5E1A in causing
down-regulation of immunoproteasome subunits. The speciﬁcity of
the effect of AdE1A on immunoproteasome subunit expression is con-
ﬁrmed by the titration shown in Fig. 4C where it can be seen that
there is an inverse correlation between levels of the proteins.
To examine the effect of viral infection on immunoproteasome ex-
pression, initially H1299 cells were treated with IFNγ after infection.
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Fig. 2.MECL1 binds to the N-terminal region and CR3 of AdE1A. A, MECL1 binds the N-terminal region and CR3 of Ad5E1A. [35S]-methionine labelled MECL1 was incubated with GST
fragments of Ad5E1A, the amino acid numbers are shown. Bound protein was fractionated by SDS-PAGE and detected by autoradiography. B, The binding site for MECL1 in the N-
terminal region of AdE1A. [35S]-methionine labelled MECL1 was incubated with GST-Ad512SE1A, mutated at residues in the N-terminal 30 amino acids. Bound protein was frac-
tionated by SDS-PAGE and detected by autoradiography. Speciﬁc mutations are indicated over each lane. C. Densitometric scan of the gels shown in 2B. D, MECL1 binding site in
Ad5CR3. The GST-Ad5E1ACR3 derivatives were incubated with [35S]-methionine labelled MECL1. Bound proteins were fractionated by SDS-PAGE and detected by autoradiography.
E, MECL1 binds to different AdE1A species. [35S]-methionine labelled MECL1 was incubated with GST-CR3 proteins as shown. Bound proteins were fractionated by SDS-PAGE and
detected by autoradiography. In each case “input” represents 5% of the actual input used.
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MECL1 by IFNγ to negligible levels (Fig. 5A). Similar results were
obtained with Ad5, Ad12 and Ad5 ΔE3 conﬁrming that there was
only a limited effect of Ad5E3 protein in the down-regulation of
LMP2, LMP7 and MECL1.
However, if cells were treated with IFNγ 24 h before infection, nei-
ther Ad5 nor Ad12 had detectable effect on the expression of LMP2,
LMP7 or MECL1 after 24 h (Fig. 5A). In these experiments the
Ad5ΔE3 virus behaved in a similar manner to Ad5wt. In a furtherexperiment, infection of H1299 cells with representatives of adenovi-
rus groups A-E conﬁrmed that down-regulation of the immunopro-
teasome components was not limited to Ad5 and Ad12 but occurred
with all viruses examined (Fig. 5B).
The effect of AdE1A on the response of human cells to IFNγ
A luciferase reporter construct with a luciferase gene downsteam
of the pGAS promoter was transfected into H1299 cells together
Ad5 E1A X X X X X
Ad5 E1B X X
Ad12 E1A X X X X X X
Ad12 E1B X X X X
Mutant Ras X X X X
LMP2
LMP7
MECL-1
1 2 3  4 5  6 7 8  9 10 11  
β-ACTIN
A
B
Fig. 3. Immunoproteasome subunit expression in Ad transformed human cell lines. Ad transformed cell lines were treated with IFNγ for 48 h and harvested. Cell lysates were frac-
tionated by SDS PAGE and western blotted for MECL1, LMP2 and LMP7. The western blots are shown in Fig. 3B and the results of densitometric scanning in Fig. 3A. The adenoviral
proteins expressed in each line are shown, under the histogram. Cell lines used were: 1, Ad12E1HER12; 2, Ad12E1HER3; 3, Ad5E1A+NrasHER286.1; 4, Ad5E1A+NrasHER313.B;
5, Ad12E1HER11; 6, Ad12E1A+NrasHER414.B; 7, Ad12E1HER5; 8, Ad5E1HER911; 9, Ad12E1AHER 283; 10, Ad5E1HER359A2; 11, Ad2E1A+Nas HER 313A. The “control” is IFNγ-
treated H1299 cells.
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was a marked inhibition of luciferase activity after IFNγ treatment
(Fig. 6A). Ad12E1A appeared to be slightly less effective than the
Ad5 proteins. In the case of the Ad transformed cell lines and tumour
cells permanently expressing AdE1A, in all cases there was a marked
inhibition of luciferase activity (Fig. 6B). This is most obviously seen
in a comparison of A549 cells with the established A549 cells expres-
sing endogenous Ad512SE1A (12S8 and 12S10 are different but com-
parable cell lines) in which case the cellular background is identical
(Fig. 6B).
It is well established that activation of the JAK/STAT pathway is
important in IFNγ induction and IFNγ signalling. It can be seen that
infection with Ad5 and Ad12 inhibited the phosphorylation of STAT
1 on serine 727 (Fig. 7A). Similarly, the transfection of Ad5E1A into
H1299 cells caused a decrease in the phosphorylation of STAT1 fol-
lowing IFNγ treatment (Fig. 7B). However, in this case reduced levels
of STAT1 protein were also observed following Ad5E1A expression.
Discussion
Viruses have evolved so that they can neutralise the host's im-
mune response. Thus adenoviruses make use of several strategies to
achieve this. Proteins encoded by the AdE3 region effectively under-
mine several of the cellular antiviral mechanisms. For example, Ad5E319K inhibits export through the endoplasmic reticulum, preventing
surface expression of MHC molecules, whereas Ad5E310.4–14.5 K
down-regulate cell surface expression of apoptosis receptors such as
Fas and TRAIL-R1/DR4 (Windheim et al., 2004; Fessler et al., 2004).
In addition, AdE1A contributes to the anti-host immune response. It
is now well established that Ad12 but not Ad5 reduces expression of
MHCI on the surface of Ad transformed rat cells, determining the onco-
genic potential of the virus in newborn rodents, and on human cells
(Bernards et al., 1983; Schrier et al., 1983; Bottley et al., 2005) AdE1A
has also been shown to cause reduced expression of other proteins in-
volved in the presentation of peptides on the cell surface. For example,
Ad12E1A inhibits expression of other genes from theMHC locus, name-
ly TAP1 and TAP2, and the immunoproteasome subunits LMP2 and
LMP7 in Ad12 but not Ad5 transformed cells (Rotem-Yehudar et al.,
1994, 1996; Vertegaal et al., 2003). Here we have extended these stud-
ies to examine the relationship of AdE1A to the third immunoprotea-
some component, MECL1 in detail, for the ﬁrst time. The MECL1 gene
is located at 16q 22.1, well away from theMHC locus. The incorporation
of the protein into the immunoproteasome is dependent on LMP2 but
not LMP7; similarly incorporation of LMP2 is dependent on MECL1, in-
dicative of the close relationship between the components. (Groettrup
et al., 1997; Grifﬁn et al., 1998; Kingsbury et al., 2000).
As with the 20S and 26S proteasomes, Ad5E1A associates with the
immunoproteasome (Fig. 1A). This co-immunoprecipitation is not a
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Fig. 4. The level of expression of immunoproteasome subunits, following transfection
of AdE1A. A, Subunit expression following Ad5E1A transfection. H1299 cells were trea-
ted with IFNγ (or mock treated) for 48 h and then transfected with the AdE1As or
empty vector as shown. The levels of protein expression determined by western blot-
ting are shown. B, Subunit expression following Ad12E1A transfection. A similar exper-
iment to that shown in 4A was carried out except Ad12E1A was substituted for
Ad5E1A. C, The effect of increasing concentrations of Ad5E1A on immunoproteasome
subunits expression. H1299 were treated with IFNγ and transfected with increasing
concentrations of Ad5E1A or pcDNA3. After 24 h cells were western blotted for immu-
noproteasome subunits, Ad5E1A and βactin.
Table 1
Transfection efﬁciency of AdE1A constructs.
Construct Transfection efﬁciency (%)
12SAd5E1A 96.1
13SAd5E1A 90.2
12SAd12E1A 84.8
13SAd12E1A 72.9
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some subunits since it has previously been shown that it binds to
20S subunits (Rasti et al., 2006). However, pull down assays
with GST-Ad5E1A and GST-Ad12E1A and in vitro translated MECL1
conﬁrm a direct interaction. Signiﬁcantly, the substitution of theimmunosubunits for the corresponding “standard” 20S subunits, β1,
β2 and β5, alters the binding pattern appreciably. AdE1A binds
strongly to β1 and β5 but not to β2 whereas it binds weakly, if at
all, to LMP2 and LMP7 (the homologues of β1 and β5 respectively)
but strongly to MECL1 (homologue of β2) (Fig. 1). Given that
AdE1A can affect the activity of the proteasome, this interaction
with the immunoproteasomemay have an effect on the peptides gen-
erated and possibly presented on the surface of Ad infected cells.
However, it is feasible that the target for AdE1A is the ability of the
immunoproteasome to preserve homeostasis and degrade damaged
or unfolded, nascent proteins (Seifert et al., 2010). Although the
immunoproteasome may generate MHCI epitopes rather more efﬁ-
ciently than proteasomes (and is a more efﬁcient proteolytic enzyme)
it is now apparent that mice lacking LMP2 or LMP7 have only a slight-
ly altered phenotype from normal (Nussbaum et al., 2005). Therefore,
it is possible that inhibition of the immunoproteasome by AdE1A
could be to inhibit the degradation of viral proteins. Support for this
suggestion is provided by the presence of aggresomes in adenovirally
infected cells (Liu et al., 2005). Similarly, in cells of mice lacking LMP7
aggresomes are formed (Seifert et al., 2010).
Using peptide fragments of Ad5E1A it has been shown that, like
many other E1A binding proteins, MECL1 interacts with the N-termi-
nal region and CR3 (Fig. 2A) (Gallimore and Turnell, 2001; Pelka et al.,
2008). Within the N-terminal region most of the hydrophobic resi-
dues around amino acids 19–30 appear to be particularly important
for the interaction, as is the case with other partner proteins (Rasti
et al., 2005). The substitutions introduced (generally A for L) are pre-
dicted not to disrupt the α helical nature of the N-terminal region but,
presumably affect the side chain binding sites (Fig. 2C). Within CR3
all of the deletions used reduce binding to MECL1, suggesting that
the integrity of the entire domain is required for optimal interaction
(Fig. 2D).
Comparison of the binding ofMECL1 to CR3 peptides fromdifferent
adenovirus species (Fig. 2E) suggests that not all subgroups target the
protein equally, although whether this also applies to the N-terminal
region is, as yet, unknown.
The association of viral proteins with proteasome and immuno-
proteasome subunits is not unique to adenoviruses. For example,
HIV-1 Tat protein has been shown to bind to LMP2 and LMP7, as
well as α4 and α7 and the 6β subunits of the 20S proteasome; this re-
sults in inhibition of both immunoproteasome and proteasome activ-
ity in in vitro assays (Apcher et al., 2003). In addition, HCV NS3
protein binds directly to LMP7, again inhibiting the activity of the
immunoproteasome (Khu et al., 2004). Other viral proteins have
been shown to interact with 20S proteasomal subunits, such as HIV
Nef and HTLV Tax, both of which associate with β7 (Rossi et al.,
1997; Rousset et al., 1996). Interestingly, HTLV Tax also interacts
with the immunoproteasome, enhancing its activity (Hemelaar
et al., 2001). It has been suggested that this might represent a strategy
for the degradation of Ikappaβα.
Adenoviruses will deregulate/inhibit particular cellular pathways
by targeting them at more than one point or in more than one way.
Therefore, we investigated whether expression of MECL1 was down-
regulated by AdE1A, as is the case for other components of the antigen
processing machinery. Using a large panel of Ad5 and Ad12 estab-
lished human cell lines (treated with IFNγ) it was observed that
MECL1 was expressed at a very low level in all cases (Fig. 3). This
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Fig. 5. The level of expression of immunoproteasome subunits following Ad infection. H1299 cells were treated (or mock treated) with IFNγ for 24 h. They were then infected or
mock infected with Ad5 or Ad12. The level of expression of immunoproteasome subunits and AdE1A is shown. A, The four lanes on the left of the gel represent the results of IFNγ
treatment after Ad infection. The central 4 tracks show cells treated with IFNγ prior to infection. B, The effects of infection with different virus serotypes. H1299 cells were infected
with the viruses shown for 24 h followed by IFNγ treatment for another 24 h. The cells were then harvested and western blotted for LMP2, LMP7, MECL-1 and βactin. The lower
panel shows a Coomassie Blue-stained gel of the same samples to conﬁrm that viral infection had proceeded.
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level in Ad5 transformants but at very low level in Ad12 transformed
cell lines. This is determined by the E1A protein, with the co-operating
oncogene having no apparent effect. These latter observations are
consistent with previous reports which have shown down regulation
of LMP2 and LMP7 in Ad12 transformed mouse cells (Rotem-Yehudar
et al., 1994, 1996) and Tapasin, PA28-α, PA28-β and MECL1 in Ad12
transformed rat cell lines (Vertegaal et al., 2003). However, in this lat-
ter studyMECL1 was consistently detected in the Ad5 transformed rat
cell lines whereas it was barely seen in Ad5 human cell transformants
described here (Fig. 3). This may represent a further signiﬁcant differ-
ence between adenovirus transformed human and rodent cells.
Transient expression of AdE1A in human cells, either through
viral infection or transfection, also resulted in the inhibition of
IFNγ-induced expression of MECL1 (and LMP2 and LMP7). Immuno-
proteasome subunits were only detectable in H1299 cells after the
addition of IFNγ (Figs. 4 and 5). If the cells were transfected with
DNA encoding Ad5 or Ad12 12S or 13SE1A the level of expression
of MECL1, LMP2 and LMP7 was markedly reduced (Figs. 4A and B).
Furthermore, it was shown that it was possible to “titrate down”
the level of expression of immunosubunits with increasing concen-
trations of Ad513SE1A DNA (Fig. 4C). Infection with Ad5 and Ad12
wt virus also down-regulated the level of expression of the immuno-
subunits but only if the virus was applied to the cells before, and not
after, IFNγ treatment (Fig. 5A). This is consistent with the known
ability of AdE1A to interfere with IFNγ signalling pathways. Theobservation that the Ad5 deletion virus which does not express E3
proteins is equally able to inhibit expression of the immunosubunits
conﬁrms that this is a result of the effect of AdE1A rather than E3
proteins. Similarly, the generality of the effects on LMP2, LMP7 and
MECL1 expression, seen after infection with viruses from other sub-
groups, indicates that this is a strategy adopted by all adenovirus
species (Fig. 5).
These observations are consistent with investigations using other
viruses. The E7 protein of HPV18 is reported to repress the bidirec-
tional promoter regulating expression of LMP2 and TAP1, affecting
immunoproteasome composition and activity (Georgopoulos et al.,
2000). Similarly, HIV-1 p24 was responsible for reduced expression
of PA28α, MECL1 and LMP7 in dendritic cells (Steers et al., 2009).
Consistent with the results presented here pre-treatment with IFNγ
reversed the effect. In contrast, previous studies showed that H1V-1
Tat modiﬁes the subunit composition of immunoproteasomes in B
and T cells, up-regulating LMP7 and MECL1 but down-regulating
LMP2 (Gavioli et al., 2004). This has the effect of modifying antigen
processing, increasing the presentation of subdominant and cryptic
epitopes. As with the study of AdE1A presented here this was consid-
ered to be attributable to the action of the viral protein on STAT sig-
nalling (Remoli et al., 2006).
The reduced expression of immunoproteasome components, to-
gether with the results of the reporter assay, shown in Fig. 6 and
the reduced level of STAT1 phosphorylation caused by AdE1A
shown in Fig. 7, strongly support the proposition that AdE1A (both
Fig. 6. The effect of AdE1A on the cellular response to IFNγ: A, The effect of transfected
E1A. H1299 cells were transfected with the IFNγ reporter construct and then AdE1A as
shown. Luciferase activity was measured and is shown. B, the response to IFNγ in Ad
transformed cell lines. Cells were transfected with the reporter construct and luciferase
activity measured.
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Fig. 7. AdE1A inhibits the phosphorylation of STAT1. A, H1299 cells were infected for
24 h with the viruses shown and then treated with IFNγ. After 24 h the cells were har-
vested and the lysates western blotted for STAT1 and for phospho (S727) STATl.
B, H1299 cells were transfected with Ad513SE1A or mock transfected. After treatment
with IFNγ for 24 h cells were harvested and western blotted for STAT1 or phospho
(S727) STATl as shown.
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nalling (Figs. 4–7). Previous studies have shown that Ad5E1A in-
hibits the cellular response to interferons after transfection into,
or infection of, human cells (Ackrill et al., 1991; Routes et al.,
1996;) and more speciﬁcally, the IFNγ-induced expression of LMP2
(Chatterjee-Kishore et al., 2000). The inhibition of IFNγ signalling
by AdE1A has been established for many years (Reich et al., 1988;
Leonard and Sen, 1996; Kalvakolanu et al., 1991; Look et al., 1998).
It appears that this inhibition can be attributed to various actions
of AdE1A, such as the interaction with p300/CBP transcriptional
coactivators, direct binding to STAT1, inhibiting its interaction with
IRF1 and subsequent binding to the GAS element, down-regulation
of STAT1 expression (which occurs here following Ad5E1A transfec-
tion [Fig. 7B]) and the inhibition of STAT1 phosphorylation. Regard-
less of whether some or all of these effects of AdE1A come into play
it seems clear that AdE1A can inhibit MECL1 through inhibition of
the IFNγ signalling pathway. It is, of course, far from clear why ade-
novirus, through the action of E1A, inhibits expression of MECL1 and
yet still speciﬁcally interacts with it. It is possible that AdE1A is not
sufﬁcient to abrogate expression of immunoproteasome compo-
nents. Direct association of AdE1A with MECL1 could be a means of
inhibiting any remaining immunoproteasomes which might be
formed in spite of the inhibition of IFNγ signalling.
Experimental procedure
Cells and viruses
Human embryo retinoblasts (HERs) were transformed with
Ad5E1, Ad12E1, Ad5E1A and Ad12E1A together with activated rasas has been described previously (Byrd et al., 1982; Gallimore et al.,
1986; Byrd et al., 1988). A549+Ad512S E1A cells have been de-
scribed previously (Rasti et al., 2005). H1299 cells derive from a
human lung carcinoma. Transformed and tumour cells were grown
in Dulbecco's modiﬁed Eagle's medium supplemented with 8% foetal
calf serum. H1299 and T47D cells were infected withwt Ad5,wt Ad12
or Ad5 with a deletion in the E3 gene (Ad5ΔE3) at an infectivity of
20pfu per cell. To generate the ΔE3 virus, Ad5wt was cloned into the
BAC plasmid pBelo BAC11, modiﬁed to excise its loxP and cos sites
and provide ﬂanking unique restriction sites and Ad arms homology.
The viral DNA was recombined from nucleotide 28, 131 to 30, 800 to
give a virus missing the E3 region. Cells were treated with γ interfer-
on (400 units/ml) where appropriate.
Reporter assays
H1299 cells were transfected with a DNA construct containing
a luciferase gene, downstream of the pGAS promoter (pGAS luc
from Stratagene), as well as appropriate controls, using Lipofectamine
2000 following the manufacturer's instructions (Invitrogen). Lucifer-
ase assays were carried out using the Promega Dual–Luciferase Re-
porter assay system. All results were normalised to a Renilla
transfection control. Cells were transfected with AdE1A DNA as ap-
propriate. The response to IFNγ was measured using a Wallac
luminometer.
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For expression of AdE1A, DNA constructs were linearised in vitro
and transcribed into mRNA using appropriate kits (mMESSAGEmMA-
CHINE T7kit and RNeasy mini kit (Qiagen)). mRNA was polyadeny-
lated and puriﬁed using standard procedures. mRNA was transfected
into human tumour cells using a BioRad Gene Pulser cell with a setting
of 300 V and a capacitance of 500 μF in 4 mm cuvettes. 1–4 μg of RNA
was transfected/106 cells. Expression was conﬁrmed by western
blotting.
Immunoprecipitation and GST-pulldown assays
H1299 cells were treated with IFNγ for 24 h, infected with Ad5 for
24 h, solubilised in 0.15 M NaCl, 20 mM Tris pH7.4, 2 mM EDTA, 1% Tri-
ton X100 and immunoprecipitated with antibodies against LMP7 and
S8; antigen/antibody complexes were collected on ProteinA-agarose
beads (Sigma). Immunoprecipitates were fractionated by PAGE on
“urea gels” (run in the absence of SDS, Grand and Gallimore, 1984)
andwestern blotted for AdE1A. GST fragments of Ad5E1Ahave beende-
scribed previously (Bruton et al., 2007; Shimwell et al., 2009) as have in
vitro translation and pull down assays (Bruton et al., 2007; Shimwell
et al., 2009). GST-Ad512SE1A constructs with point mutations in the
N-terminal 30 amino acids were described by Rasti et al. (2005). Con-
structs for in vitro translation of 20S proteasome subunits and immuno-
proteasome subunits have been described (Kuckelkorn et al., 1995;
Apcher et al., 2003; Seifert et al., 2010).
Antibodies
Immunoproteasome components LMP2, LMP7 and MECL1 were
detected by Western blotting using antibodies from Abcam and a
generous gift from Professor Marcus Groettrup. LMP7 was immuno-
precipitated with an antibody from Santa Cruz and S8 precipitated
with a rabbit antibody (gift from Dr Wenlan Wang). Proteasomes
were immunoprecipitated with an antibody against the α subunits
(Biomol). STAT 1 and Phospho-STAT1 (S727) were detected with anti-
bodies from Active Motif. Ad12E1A was detected with the mouse
monoclonal antibody 5D02 and Ad5E1A with the mouse monoclonal
antibody M58.
Immunoﬂuorescence microscopy
Efﬁciency of transfection of AdE1As was determined by transfect-
ing H1299 cells using Lipofectamine 2000. 24 h later cells were ﬁxed
and stained for Ad12 or Ad5 E1A, essentially as described previously
(Forrester et al., 2011). Cells are viewed by confocal microscopy and
positive AdE1A expressing cells counted.
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